Posted: May 02, 2018|Categories: Current news
On 30 April 2018, the EMA published the final, revised version of the Q&A document with its focus on setting health-based exposure limits for risk identification and the risk-based prevention of cross-contamination. The Q&A covers 13 questions and answers relating to the “Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities”, which has been in force since June 2015.
In January 2017, the EMA released a draft for public consultation (we reported). But this paper constituted a roll backwards!